Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty.

JAMA network open·2026
Same author

Creation of a Merged Harmonized Large Database of Subject-Level Data from Acute Secondary Prevention Studies in Minor Non-Cardioembolic Stroke or TIA.

International journal of cerebrovascular disease and stroke·2026
Same author

CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone.

Frontiers in pharmacology·2026
Same author

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.

JAMA network open·2026
Same author

The Future of Clinical Translational Pharmacology.

Clinical pharmacology and therapeutics·2026
Same author

Associations of antidiabetic medications with abdominal aortic aneurysm growth and clinical outcomes: A systematic review and meta-analysis.

Journal of vascular surgery·2026

Related Experiment Video

Updated: Jul 5, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Beta-blocker pharmacogenetics in heart failure.

Jaekyu Shin1, Julie A Johnson

  • 1Department of Pharmacy Practice, College of Pharmacy, Center for Pharmacogenetics, University of Florida, P.O. Box 100486, Gainesville, FL 32610-0486, USA.

Heart Failure Reviews
|April 26, 2008
PubMed
Summary

Genetic variations influence how patients with heart failure (HF) respond to beta-blocker medications like metoprolol, bisoprolol, and carvedilol. Understanding these genetic differences can personalize HF treatment for better outcomes.

Related Experiment Videos

Last Updated: Jul 5, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Area of Science:

  • Cardiology
  • Pharmacogenetics
  • Genetics

Background:

  • Beta-blockers are essential for treating heart failure (HF).
  • Patient responses to beta-blockers vary significantly.
  • Genetic factors are increasingly recognized as contributors to this variability.

Purpose of the Study:

  • To review existing pharmacogenetic data for beta-blockers in HF patients.
  • To discuss the clinical implications of beta-blocker pharmacogenetics for HF treatment.

Main Methods:

  • Literature review of pharmacogenetic studies.
  • Analysis of genetic polymorphisms and their impact on beta-blocker response in HF.

Main Results:

  • Genetic polymorphisms are linked to variable responses in left ventricular ejection fraction, survival rates, and HF hospitalizations.
  • Specific genetic variations correlate with differential treatment efficacy and adverse events.

Conclusions:

  • Pharmacogenetics offers a promising avenue for tailoring beta-blocker therapy in heart failure.
  • Personalized medicine approaches based on genetic profiles may optimize HF management and improve patient outcomes.